Mycophenolate Mofetil, Sirolimus, Tacrolimus, and Thymoglobulin Combination Therapy

This is a combination immunosuppressive regimen primarily used in **kidney transplantation** for the prevention of organ rejection, especially in **high-risk patients**. It comprises four distinct immunosuppressants, each targeting different aspects of the immune response: 1. **Mycophenolate mofetil (MMF)**: An antimetabolite that inhibits T and B cell proliferation. 2. **Sirolimus**: An immunosuppressant that inhibits T cell activation and proliferation by targeting mTOR. 3. **Tacrolimus**: A calcineurin inhibitor that prevents T cell activation. 4. **Thymoglobulin** (Anti-thymocyte globulin, rabbit): A polyclonal antibody that depletes T cells. This multi-drug approach provides **multi-targeted immunosuppression**: * **Thymoglobulin** typically provides initial T-cell depletion (induction therapy). * **Tacrolimus** inhibits calcineurin, preventing T-cell activation. * **Mycophenolate mofetil** inhibits purine synthesis, affecting T and B cell proliferation. * **Sirolimus** inhibits the mammalian target of rapamycin (mTOR), affecting T-cell proliferation. While offering robust immunosuppression crucial for patients at high immunological risk for rejection, such intensive immunosuppression also carries significant risks of **infection** and other **adverse effects**.

Other names

Quadruple Immunosuppressive Regimen for Kidney TransplantHigh-Risk Kidney Transplant Immunosuppression